HAEMOPHILIA:直接抗病毒药物时代血友病患者肝细胞癌的患病率和危险因素:一项全国住院患者样本研究

2022-08-03 将军的九分裤 MedSci原创

肝细胞癌(HCC)是慢性丙型肝炎病毒(HCV)感染的主要并发症。尽管DAAs广泛使用,HCV仍然是血友病人群HCC的主要危险因素。

肝细胞癌(HCC)是慢性丙型肝炎病毒(HCV)感染的主要并发症。在血友病 (H) 男性中,HCV 是肝病的主要原因。直接作用抗病毒药物 (DAA) 可降低 HCV 病毒载量,但对 HCC 的影响尚不清楚。因此,一项回顾性研究对 2016-2018 年国家住院患者样本 (NIS) 数据库中的 ICD-10 代码确定的成年 H 和非血友病 (NH) 男性出院(伴有和不伴有 HCC)进行了 DAA 可用性分析。

分析包括排放水平权重以反映国家估计。分类变量通过 Rao-Scott 卡方进行评估,连续变量通过加权简单线性回归进行评估。HCC相关性通过加权多变量逻辑回归确定。

图1 (A): 2016-2018年血友病患者中丙型肝炎(HCV)的趋势。该图描述了血友病患者丙型肝炎的年度趋势。血友病患者(红色)和非血友病患者(黑色)的加权百分比按年排列。(B): 2016-2018年血友病中肝细胞癌(HCC)的趋势。该图描述了肝细胞癌的发展趋势,在血友病患者中血友病患者(红色)和非血友病患者(黑色)的加权百分比按年排列

在 7,674,969 名成年男性出院者中,2016-2018 年发现 3730 例 H(0.04%),其中 10.06% 为 HCV,1.07% 为 HCC,显着高于 NH(分别为 1.22% 和 0.27%),所有 P < .001。在 H 和 NH 的 3 年期间(2016-2018 年),年度 HCC 发生率相似。在 H 中,HCC 与年龄较大和 HCV、HBV、NASH、终末期肝病和 Charlson 合并症 (CCI) 的发病率较高有关,每个 P < .001。

在 HCC 中,与 NH 相比,H 更年轻且更可能是 HIV+,每个 P < .001,但不太可能酗酒 (P = .018) 或高脂血症 (P = .008)。在多变量回归中,H 中 HCC 的危险因素包括 NASH (OR 21.6)、HCV (OR 3.96)、CCI (OR1.54),所有 P < .001,而 HIV 和高脂血症具有保护作用。

总之,尽管DAAs广泛使用,HCV仍然是血友病人群HCC的主要危险因素。重要的是,NASH有助于血友病患者发生HCC的风险,与其他风险组一样,与共病疾病一样。这些发现证实了在这一高危人群中继续进行HCC监测和前瞻性研究的必要性。

 

原始出处:

Yang X, Jeong K, Yabes JG, Ragni MV. Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: A national inpatient sample study. Haemophilia. 2022 Jun 21. doi: 10.1111/hae.14607. Epub ahead of print. PMID: 35727998.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
    2022-08-29 zhzhxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
    2023-02-07 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
    2022-11-02 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
    2022-08-02 yahu
  8. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1669496, encodeId=740c1669496bd, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Aug 29 07:03:39 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863678, encodeId=c38d18636e8fd, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Feb 07 12:03:39 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008594, encodeId=aa04200859421, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 02 11:03:39 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967848, encodeId=c025196e848dc, content=<a href='/topic/show?id=3858e2436f4' target=_blank style='color:#2F92EE;'>#直接抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72436, encryptionId=3858e2436f4, topicName=直接抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Jul 01 00:03:39 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979359, encodeId=e76219e935957, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 12 06:03:39 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250831, encodeId=97d31250831fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292571, encodeId=e54a12925e1d7, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363376, encodeId=7f6613633e64a, content=<a href='/topic/show?id=2b00554848e' target=_blank style='color:#2F92EE;'>#抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55484, encryptionId=2b00554848e, topicName=抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489492, encodeId=3e4414894925e, content=<a href='/topic/show?id=6f71e24390c' target=_blank style='color:#2F92EE;'>#直接抗病毒药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72439, encryptionId=6f71e24390c, topicName=直接抗病毒药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe638558169, createdName=crystal0565, createdTime=Tue Aug 02 05:03:39 CST 2022, time=2022-08-02, status=1, ipAttribution=)]

相关资讯

中药及活性成分可以发挥抗肿瘤活性,抑制肝癌

肝细胞癌 (HCC) 是全球主要的致死性肿瘤之一,其治疗仍然是一项巨大的医学挑战。手术和化学疗法是目前HCC患者的标准治疗方法,但预后仍然不佳。最近,中医药(TCM)被广泛应用于有效治疗HCC。

ASCO 2022:肝细胞癌患者肝移植后 30 天再入院率的预测因素

肝移植术后再入院与较高的死亡率相关,并导致较高的医疗保健负担。

Clin Cancer Res:甲胎蛋白可作为肝细胞癌采用Atezolizuma+贝伐单抗治疗的预后生物标志物

治疗第6周时的AFP反应可作为受Atezolizuma+贝伐单抗治疗的肝细胞癌患者预后的替代生物标志物

J Hepatol:新型的儿童肝癌分子亚型已被科学家识别到!

本文分析结果表明,携带肝细胞癌特征的儿童或许会得益于不同于肝母细胞癌和肝细胞癌患者治疗指南的治疗策略。

CGH:恶病质在肝细胞癌患者中普遍存在并与更差的预后相关

肝细胞癌是原发性肝癌中的一种,原发性肝癌主要包括肝细胞性肝癌、胆管细胞性肝癌和混合性肝癌。

NEJM Evid:Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗

肝细胞癌是全球癌症相关死亡的最常见原因之一。大多数患者在诊断时因晚期或转移性疾病或在具有治愈目的的局部干预后疾病复发而需要全身治疗。多激酶抑制剂,例如索拉非尼和乐伐替尼在全球范围内被用于治疗无法切除的

拓展阅读

Haemophilia:肥胖对血友病患者慢性疼痛的影响:一项多中心回顾性分析

这项研究发现,16%的PWH患者服用了阿片类止痛药。虽然该研究没有发现超重/肥胖状态和慢性阿片类药物使用之间的联系,但它提供了进一步的证据,表明慢性疼痛是PWH中的一个普遍问题。

Haemophilia:血友病患者的体力活动和因子VIII水平:一项真实世界的前瞻性观察研究

这项研究提供了1011pa治疗开始时FVIII水平的真实数据。PwH主要活跃于低风险运动中,在II和III类运动中分别观察到较高的FVIII水平。只有3例PA诱导出血发生,尽管有几例PA以低FVIII

Haemophilia:血友病患者肌肉减少的频率——对肌肉骨骼健康和功能表现的影响

研究者认为,定期用药和控制运动可以有效地减少肌肉减少症的发生,超声是血友病A患者肌少症的一种极好的诊断工具。

Haemophilia:血友病髌骨股骨关节形态学分析——病例对照研究

血友病关节病的形态学改变包括髌骨变小和中间倾斜,外侧髁和经髁轴变窄,并伴有髁间深度减小。这些改变必须牢记,尤其是在关节置换术前和术中评估时

Sci Transl Med:革命性疗法:利用siRNA靶向减少血浆纤溶酶原,为血友病患者带来希望

siRNA疗法通过特异性地靶向并降解疾病相关基因的mRNA,从而抑制异常蛋白的产生,为精准医疗提供了新的策略。

Hematology:采血针死腔对血友病患儿FVIII水平及药代动力学的影响

研究证实了部分抽吸真空管APTT结果延长和FVIII活性下降是由一次性采血针的死腔引起的。并建议使用真空管进行凝血指标和PK谱时,应提前消除采血针的死区。

血友病合并抑制物诊断与治疗中国指南(2023年版)

中华医学会血液学分会血栓与止血学组 · 2024-01-01

2022 MASAC 文件 273 - 血友病患者基因分型建议

国家血友病基金会的医学和科学咨询委员会 (MASAC) NHF’s Medical and Scientific Advisory Council (MASAC) · 2022-07-06

2022 MASAC 文件 272 - MASAC 关于获得许可用于治疗血友病和其他出血性疾病的产品的建议

国家血友病基金会的医学和科学咨询委员会 (MASAC) NHF’s Medical and Scientific Advisory Council (MASAC) · 2022-04-27

2022 MASAC 文件 271 - 关于在家中为血友病和抑制剂患者使用抑制剂旁路药物的建议

国家血友病基金会的医学和科学咨询委员会 (MASAC) NHF’s Medical and Scientific Advisory Council (MASAC) · 2022-04-27